DOCSLIB.ORG

Proteinuria and Mammalian Target of Rapamycin Inhibitors in Renal Transplantation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Proteinuria and Mammalian Target of Rapamycin Inhibitors in Renal Transplantation TrendsFritz in Transplant. Diekmann: 2011;5:139-43 Proteinuria and Mammalian Target of Rapamycin Inhibitors in Renal Transplantation Proteinuria and Mammalian Target of Rapamycin Inhibitors in Renal Transplantation Fritz Diekmann Department of Nephrology and Renal transplantation, Hospital Clínic, Barcelona, Spain Abstract Mammalian target of rapamycin (mTOR) inhibitor use in renal transplant recipients has been associated with more proteinuria compared with calcineurin inhibitors. This overview will focus on mTOR inhibitor-associated proteinuria in various situations after kidney transplantation: de novo treatment with mTOR inhibitor in combination with a calcineurin inhibitor, de novo mTOR inhibitor-containing and calcineurin inhibitor-free treatment, early conversion from a calcineurin inhibitor-based regimen to mTOR inhibitor-based regimen and late conversion. Some possible mechanisms of mTOR inhibitor-induced proteinuria will also be reviewed. (Trends in Transplant. 2011;5:139-43) Corresponding author: Fritz Diekmann, [email protected] Key words Kidney transplantation. Proteinuria. mTOR inhibitors. Everolimus. Sirolimus. 24-hour urine protein excretion or urinary ntroduction I protein/creatinine ratio is part of the assessment during posttransplant follow-up. Moreover, The mammalian target of rapamycin proteinuria is a prognostic factor for graft and (mTOR) inhibitors everolimus (EVR) and si- patient survival8. rolimus (SRL) are used in transplant medi- cine as immunosuppressive drugs, especial- This review will focus on mTOR inhibi- ly in kidney transplantation. These drugs tor-associated proteinuria in different settings have been associated with a significantly after kidney transplantation: higher incidence of proteinuria compared with calcineurin inhibitors (CNI)1-7. Proteinuria – De novo mTOR inhibitor treatment in com- is a well-known phenomenon in renal kidney bination with a CNI; transplant patients, and measurement of – De novo mTOR inhibitor treatment free of a CNI; Correspondence to: Fritz Diekmann – Early conversion from a CNI-based regimen Servicio de Nefrología y Trasplante Renal Hospital Clínic to an mTOR inhibitor-based regimen; Villarroel, 170 08036 Barcelona, España – Late conversion from a CNI-based regimen E-mail: [email protected] to an mTOR inhibitor-based regimen. 139 Trends in Transplantation 2011;5 Mammalian Target on 24-hour urine proteinuria were not col- of Rapamycin Inhibitor lected, proteinuria was not reported more with Calcineurin Inhibitor frequently as an adverse event in the SRL De Novo arms12,13. Dantal, et al. evaluated 139 patients A more recent study was performed by with a high risk of delayed graft function, de- Büchler, et al. A total of 145 patients were fined as at least one of the following risk fac- randomized to receive de novo treatment tors: donor over 55 years of age, cold isch- with antithymocyte globulin plus mycopheno- emia time between 24 and 40 hours, or late mofetil plus prednisolone (the latter for previous kidney transplant9. At the same only six months) with either cyclosporin A time, these are risk factors for developing (CsA; n = 74) or SRL (n = 71). Patient and proteinuria10. The incidence of delayed graft graft survival in the CsA and SRL groups function was compared in immediate EVR were 97 vs. 97%, and 93 vs. 90%, respec- (IE; cyclosporine in combination with low- tively (p = ns). dose EVR de novo) and delayed EVR treat- ment (DE; cyclosporine in combination with Acute rejection rates were 8.6 vs. 14.3% mycophenolate sodium de novo and conver- (p = ns). Glomerular filtration rate (GFR) was sion from mycophenolate to EVR after week 57 vs. 60 ml/min (p = ns). At one year, the in- four). Patients in both arms received induc- cidence of proteinuria > 0.5 g/day was 5.6 vs. tion with basiliximab and also steroid treat- 38.8% (p < 0.001) in the CsA vs. the SRL arm. ment. Proteinuria at one year was not sig- Mean 24-hour proteinuria was 01.8 ± 0.3 g/day nificantly different between the two groups, in the CsA arm vs. 0.64 ± 0.8 g/day in the SRL 280 mg/day in the IE arm compared with arm (p < 0.001)14. 265 mg/day in the DE arm; however, the num- ber of patients with available values was less From these studies one can conclude than 30% in both arms. Urinary protein per that de novo CNI-free treatment with an mTOR creatinine analysis showed a similar result: inhibitor can be associated with a higher de- 0.3 vs. 0.3 g/g, with approximately half of the gree of proteinuria. It remains to be deter- patients with available values. mined if this increase is clinically relevant in terms of its influence on long-term transplant In the US and global Rapamune trials function. (SRL in combination with a CNI), proteinuria was not measured as part of the routine as- sessment of kidney function. However, it also Preventive Conversion was not mentioned as an adverse event in from Calcineurin Inhibitors these early studies on the CNI and mTOR to Mammalian Target inhibitor combination11. of Rapamycin Inhibitors during the First Posttransplant Year Mammalian Target In the ZEUS study, Budde, el al. evalu- of Rapamycin Inhibitor without ated one-year kidney graft function in pa- Calcineurin Inhibitor De Novo tients who received an immunosuppressive pro- tocol consisting of basiliximab induction with The first studies using mTOR inhibi- CsA, mycophenolate sodium, and steroids. Of tors without a CNI in the de novo setting 300 patients, 155 were converted from CsA- were performed in the 1990s. Although data based to CNI-free EVR-based treatment at 140 Fritz Diekmann: Proteinuria and Mammalian Target of Rapamycin Inhibitors in Renal Transplantation 4.5 months after transplantation. Graft func- There was also no difference in graft tion was clearly better in the EVR group at one function in the intent-to-treat analysis. In year (71.9 vs. 61.3 ml/min; p < 0.0001; not the SRL group, proteinuria increased from significant difference at baseline). Mean pro- 0.35 g/day at baseline to 0.87 g/day at two teinuria was significantly higher in the EVR years after baseline, whereas it increased group (455 ± 510 vs. 284 ± 472 mg/day)15. from 0.28 to 0.42 g/day in the CsA group. Similar results were found in the Spare- The difference between the proteinuria the-Nephron study16. in the SRL group and the CsA group was significant: p < 0.001 after two years. More- In the CONCEPT study, all patients over, proteinuria at baseline was a predictive were treated with daclizumab induction, CsA, factor for improvement of graft function after mycophenolate mofetil, and steroids de novo. conversion (the difference after two years be- At 12 weeks, 96 patients were converted from tween the proteinuria in the SRL group and CsA to SRL, whereas 97 patients remained the CsA group was significant; p < 0.001). on CsA treatment. After eight months, steroids Furthermore, proteinuria at baseline was a were withdrawn. Kidney graft function at one predictive factor for improvement of graft year was superior in the SRL arm (modification function after conversion18. of diet in renal disease, 61.2 vs. 53.9 ml/min; p = 0.002). Proteinuria was significantly dif- Other non-randomized conversion stud- ferent at six months after transplantation ies have shown an increase of proteinuria in (0.6 vs. 0.3 g/day; n = 65 and 79, respec- late conversion patients, and suggested a pre- tively; p < 0.05). However, this difference dictive value of proteinuria at conversion for disappeared at one year: 0.4 g/day in the SRL long-term graft function post-conversion19-21. arm (n = 54) vs. 0.3 g/day in the CsA arm (n = 69). Again it remains to be determined if this tendency towards a higher proteinuria Possible Mechanisms might have some influence on outcome despite of Mammalian Target of better kidney function17. Rapamycin Inhibitor-Associated Proteinuria Late Conversion, Mainly It was speculated that at least part of for Slowly Declining the increase of proteinuria after withdrawal Allograft Function of the CNI and subsequent introduction of an mTOR inhibitor could be explained by In the CONVERT, study Schena, et al. possible hemodynamic changes due to the randomized 830 kidney transplant patients withdrawal of the CNI. Calcineurin inhibitors between six months and ten years after trans- are known to exert anti-proteinuric effects, plantation to either continue on their CNI treat- partly by increasing the resistance of the ment in combination with an antimetabolite afferent arteriole and thus reducing intra- and steroids (n = 275), or to withdraw the CNI glomerular pressure. This effect could be and convert to SRL (n = 555). Enrolment was demonstrated by Saurina, et al.22. However, halted in patients with a GFR < 40 m/min due a later study of conversion from mainly an to safety reasons. In the patients with GFR azathioprine-based regimen to SRL for skin > 40 ml/min, there was no difference in patient cancer revealed a marked increase of pro- survival, graft survival, or acute rejection rate teinuria after conversion to SRL from a non- at two years. CNI-containing regimen, suggesting that there 141 Trends in Transplantation 2011;5 is a genuine proteinuria-causing effect of In the late conversion setting, baseline mTOR inhibition23. proteinuria is predictive of graft function after conversion. In the early conversion setting, Various authors suggested the vascular graft function is better in converted patients, endothelial growth factor (VEGF) system to be despite a trend towards higher proteinuria. implicated in mTOR inhibitor-associated pro- The long-term effect after five or ten years teinuria. Letavernier, et al. exposed primary remains unknown. cultures of human podocytes to therapeutic- range concentrations of sirolimus24. They ob- served that VEGF synthesis and Akt phospho- References 1. Diekmann F, Gutierrez-Dalmau A, Lopez S, et al.
Load more

Recommended publications
  • WHO Drug Information Vol
    WHO Drug Information Vol. 31, No. 3, 2017 WHO Drug Information Contents Medicines regulation 420 Post-market monitoring EMA platform gains trade mark; Automated 387 Regulatory systems in India FDA field alert reports 421 GMP compliance Indian manufacturers to submit self- WHO prequalification certification 421 Collaboration 402 Prequalification process quality China Food and Drug Administration improvement initiatives: 2010–2016 joins ICH; U.S.-EU cooperation in inspections; IGDRP, IPRF initiatives to join 422 Medicines labels Safety news Improved labelling in Australia 423 Under discussion 409 Safety warnings 425 Approved Brimonidine gel ; Lactose-containing L-glutamine ; Betrixaban ; C1 esterase injectable methylprednisolone inhibitor (human) ; Meropenem and ; Amoxicillin; Azithromycin ; Fluconazole, vaborbactam ; Delafloxacin ; Glecaprevir fosfluconazole ; DAAs and warfarin and pibrentasvir ; Sofosbuvir, velpatasvir ; Bendamustine ; Nivolumab ; Nivolumab, and voxilaprevir ; Cladribine ; Daunorubicin pembrolizumab ; Atezolizumab ; Ibrutinib and cytarabine ; Gemtuzumab ozogamicin ; Daclizumab ; Loxoprofen topical ; Enasidenib ; Neratinib ; Tivozanib ; preparations ; Denosumab ; Gabapentin Guselkumab ; Benznidazole ; Ciclosporin ; Hydroxocobalamine antidote kit paediatric eye drops ; Lutetium oxodotreotide 414 Diagnostics Gene cell therapy Hightop HIV home testing kits Tisagenlecleucel 414 Known risks Biosimilars Warfarin ; Local corticosteroids Bevacizumab; Adalimumab ; Hydroquinone skin lighteners Early access 415 Review outcomes Idebenone
    [Show full text]
  • Practice Guideline: Disease-Modifying Therapies for Adults with Multiple Sclerosis
    Practice guideline: Disease-modifying therapies for adults with multiple sclerosis Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology Alexander Rae-Grant, MD1; Gregory S. Day, MD, MSc2; Ruth Ann Marrie, MD, PhD3; Alejandro Rabinstein, MD4; Bruce A.C. Cree, MD, PhD, MAS5; Gary S. Gronseth, MD6; Michael Haboubi, DO7; June Halper, MSN, APN-C, MSCN8; Jonathan P. Hosey, MD9; David E. Jones, MD10; Robert Lisak, MD11; Daniel Pelletier, MD12; Sonja Potrebic, MD, PhD13; Cynthia Sitcov14; Rick Sommers, LMSW15; Julie Stachowiak, PhD16; Thomas S.D. Getchius17; Shannon A. Merillat, MLIS18; Tamara Pringsheim, MD, MSc19 1. Department of Neurology, Cleveland Clinic, OH 2. Department of Neurology, Charles F. and Joanne Knight Alzheimer Disease Research Center, Washington University in St. Louis, MO 3. Departments of Medicine and Community Health Sciences, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada 4. Department of Neurology, Mayo Clinic, Rochester, MN 5. UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco 6. Department of Neurology, Kansas University Medical Center, Kansas City 7. Department of Neurology, School of Medicine, University of Louisville, KY 8. Consortium of Multiple Sclerosis Centers, Hackensack, NJ 9. Department of Neuroscience, St. Luke’s University Health Network, Bethlehem, PA 10. Department of Neurology, School of Medicine, University of Virginia, Charlottesville 11. Consortium of Multiple Sclerosis Centers, Hackensack, NJ, and Department of Neurology, School of Medicine, Wayne State University, Detroit, MI 12. Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles 13. Neurology Department, Southern California Permanente Medical Group, Kaiser, Los Angeles 14.
    [Show full text]
  • Weak Interaction of the Antimetabolite Drug Methotrexate with a Cavitand Derivative
    International Journal of Molecular Sciences Article Weak Interaction of the Antimetabolite Drug Methotrexate with a Cavitand Derivative Zsolt Preisz 1,2, Zoltán Nagymihály 3,4, Beáta Lemli 1,4 ,László Kollár 3,4 and Sándor Kunsági-Máté 1,2,4,* 1 Institute of Organic and Medicinal Chemistry, Medical School, University of Pécs, Szigeti 12, H-7624 Pécs, Hungary; [email protected] (Z.P.); [email protected] (B.L.) 2 Department of General and Physical Chemistry, Faculty of Sciences, University of Pécs, Ifjúság 6, H 7624 Pécs, Hungary 3 Department of Inorganic Chemistry, Faculty of Sciences, University of Pécs, Ifjúság 6, H 7624 Pécs, Hungary; [email protected] (Z.N.); [email protected] (L.K.) 4 János Szentágothai Research Center, University of Pécs, Ifjúság 20, H-7624 Pécs, Hungary * Correspondence: [email protected]; Tel.: +36-72-503600 (ext. 35449) Received: 2 June 2020; Accepted: 16 June 2020; Published: 18 June 2020 Abstract: Formation of inclusion complexes involving a cavitand derivative (as host) and an antimetabolite drug, methotrexate (as guest) was investigated by photoluminescence measurements in dimethyl sulfoxide solvent. Molecular modeling performed in gas phase reflects that, due to the structural reasons, the cavitand can include the methotrexate in two forms: either by its opened structure with free androsta-4-en-3-one-17α-ethinyl arms or by the closed form when all the androsta-4-en-3-one-17α-ethinyl arms play role in the complex formation. Experiments reflect enthalpy driven complex formation in higher temperature range while at lower temperature the complexes are stabilized by the entropy gain.
    [Show full text]
  • Public Assessment Report
    Public Assessment Report Tifix 150mg and 500mg film-coated tablets Capecitabine BE/H/195/01-02/DC BE licence no: BE423552-BE423561 Applicant: Alfred E. Tiefenbacher, Germany Date: 27-04-2012 Toepassingsdatum : 15-09-10 Page 1 of 17 Blz. 1 van 17 This assessment report is published by the Federal Agency for Medicines and Health Products following Article 21 (3) and (4) of Directive 2001/83/EC, amended by Directive 2004/27/EC and Article 25 paragraph 4 of Directive 2001/82/EC as amended by 2004/28/EC. The report comments on the registration dossier that was submitted to the Federal Agency for Medicines and Health Products and its fellow organisations in all concerned EU member states. It reflects the scientific conclusion reached by the Federal Agency for Medicines and Health Products and all concerned member states at the end of the evaluation process and provides a summary of the grounds for approval of a marketing authorisation. This report is intended for all those involved with the safe and proper use of the medicinal product, i.e. healthcare professionals, patients and their family and carers. Some knowledge of medicines and diseases is expected of the latter category as the language in this report may be difficult for laymen to understand. This assessment report shall be updated by a following addendum whenever new information becomes available. To the best of the Federal Agency for Medicines and Health Products’ knowledge, this report does not contain any information that should not have been made available to the public. The Marketing Autorisation Holder has checked this report for the absence of any confidential information.
    [Show full text]
  • Leflunomide Affect Fertility Or Pregnancy?
    Does Leflunomide affect fertility or pregnancy? Leflunomide may cause serious birth defects. Do not take Leflunomide if you are planning to conceive, during pregnancy or when breastfeeding. It is necessary for men and women to use contraception while on National University Hospital Leflunomide.. The drug may remain in the body for up to two years after the last dose. Women Medication Information must not become pregnant and men must not 5 Lower Kent Ridge Road, Singapore 119074 for Patients father children within two years of stopping Website: www.nuh.com.sg Leflunomide; unless medicine is given to get rid LEFLUNOMIDE of it from your body system (consult your doctor). Company Registration No. 198500843R You must not take Leflunomide unless you are on reliable contraception. Pharmacy (Main Building): 6772 5181/5182 Can I have immunisations while on Pharmacy (Kent Ridge Wing): 6772 5184 Leflunomide? Pharmacy (NUH Medical Centre): 6772 8205 Pneumococcal, influenza, hepatitis A and B, tetanus vaccinations are allowed. Avoid immunisations with live vaccines such as polio, varicella (chicken pox), measles, mumps and rubella (MMR). The information provided in this publication is meant purely for educational purposes and may not be used as a substitute for medical diagnosis or treatment. You should seek the advice of your doctor or a qualified healthcare provider before starting any treatment or if you have any questions related to your health, physical fitness or medical conditions. Information is correct at time of printing and subject to revision without prior Are there any alternatives to Leflunomide? notice. Copyright 2014.NationalUniversityHospital Your doctor will advise on the safest and most All Rights reserved.
    [Show full text]
  • Hepatic Arterial Infusion for Unresectable Colorectal Liver Metastases Combined Or Not with Systemic Chemotherapy
    ANTICANCER RESEARCH 29: 4139-4144 (2009) Hepatic Arterial Infusion for Unresectable Colorectal Liver Metastases Combined or Not with Systemic Chemotherapy PIERLUIGI PILATI, ENZO MAMMANO, SIMONE MOCELLIN, EMANUELA TESSARI, MARIO LISE and DONATO NITTI Clinica Chirurgica II, Department of Oncological and Surgical Sciences, University of Padova, 35128 Padova, Italy Abstract. Background: The hypothesis was tested that CRC have liver metastases at autopsy, and the majority of systemic chemotherapy might contribute to improving overall these patients die as a result of their metastatic disease. survival (OS) of patients with unresectable colorectal liver Surgical resection represents the standard treatment of metastases treated with hepatic arterial infusion (HAI). resectable disease and is followed by 5-year overall Patients and Methods: We considered 153 consecutive patients survival (OS) rates of 20% to 40% (2, 3). Unfortunately, retrospectively divided into group A (n=72) treated with HAI only 20% of patients with liver metastases from CRC alone (floxuridine [FUDR] + leucovorin [LV]), and group B present with liver-confined resectable disease and/or are (n=81) treated with HAI combined with systemic candidates for major surgical operation (depending on chemotherapy (5-fluorouracil [5FU] + LV). Results: No comorbidities) (4, 5). significant difference in OS was observed between the two The therapeutic management of unresectable metastases is groups. Median OS was better in patients with <50% of liver more controversial and is generally associated with a dismal involvement (21.3 vs. 13.2 months; p<0.0001) and in prognosis. In fact, despite the improvements achieved with responders vs. non-responders (24.4 vs. 13.4 months; modern systemic chemotherapy (SCT) regimens (e.g.
    [Show full text]
  • Systematic Review of Immunomodulatory Drugs for the Treatment of People with Multiple Sclerosis: Is There Good Quality Evidence on Evectiveness and Cost?
    574 J Neurol Neurosurg Psychiatry 2001;70:574–579 J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.70.5.574 on 1 May 2001. Downloaded from Systematic review of immunomodulatory drugs for the treatment of people with multiple sclerosis: Is there good quality evidence on eVectiveness and cost? J Bryant, A Clegg, R Milne Abstract clinical and cost eVectiveness of health technolo- Objective—To review the clinical eVec- gies and provide guidance to the NHS. At the tiveness and costs of a range of disease time of writing, it is considering â-interferon and modifying drugs in multiple sclerosis. glatiramer in the treatment of multiple sclerosis. Drugs included are azathioprine, cladrib- Excluded from the NICE appraisal are several ine, cyclophosphamide, intravenous im- other disease modifying drugs that may be used munoglobulin, methotrexate, and in the treatment of this disease. A comprehen- mitoxantrone. sive appraisal of disease modifying drugs for the Methods—Electronic databases and bibli- treatment of multiple sclerosis should consider ographies of related papers were searched all competing alternatives. for randomised controlled trials (RCTs) This study is, to the best of our knowledge, the first systematic review of a range of disease and systematic reviews, and experts and modifying drugs for multiple sclerosis. We were pharmaceutical companies were con- commissioned by the NHS Research and tacted for further information. Inclusion Development Health Technology Assessment and quality criteria were assessed, data (HTA) programme to undertake a rapid system- extraction undertaken by one reviewer atic review to appraise the evidence on the eVec- and checked by a second reviewer, with tiveness and cost of azathioprine, cladribine, discrepancies being resolved through dis- cyclophosphamide, intravenous immunoglobu- cussion.
    [Show full text]
  • Drugs and Life-Threatening Ventricular Arrhythmia Risk: Results from the DARE Study Cohort
    Open Access Research BMJ Open: first published as 10.1136/bmjopen-2017-016627 on 16 October 2017. Downloaded from Drugs and life-threatening ventricular arrhythmia risk: results from the DARE study cohort Abigail L Coughtrie,1,2 Elijah R Behr,3,4 Deborah Layton,1,2 Vanessa Marshall,1 A John Camm,3,4,5 Saad A W Shakir1,2 To cite: Coughtrie AL, Behr ER, ABSTRACT Strengths and limitations of this study Layton D, et al. Drugs and Objectives To establish a unique sample of proarrhythmia life-threatening ventricular cases, determine the characteristics of cases and estimate ► The Drug-induced Arrhythmia Risk Evaluation study arrhythmia risk: results from the the contribution of individual drugs to the incidence of DARE study cohort. BMJ Open has allowed the development of a cohort of cases of proarrhythmia within these cases. 2017;7:e016627. doi:10.1136/ proarrhythmia. Setting Suspected proarrhythmia cases were referred bmjopen-2017-016627 ► These cases have provided crucial safety by cardiologists across England between 2003 and 2011. information, as well as underlying clinical and ► Prepublication history for Information on demography, symptoms, prior medical and genetic data. this paper is available online. drug histories and data from hospital notes were collected. ► Only patients who did not die as a result of the To view these files please visit Participants Two expert cardiologists reviewed data the journal online (http:// dx. doi. proarrhythmia could be included. for 293 referred cases: 130 were included. Inclusion org/ 10. 1136/ bmjopen- 2017- ► Referral of cases by cardiologists alone may have criteria were new onset or exacerbation of pre-existing 016627).
    [Show full text]
  • Palladium-Mediated Dealkylation of N-Propargyl-Floxuridine As a Bioorthogonal Oxygen-Independent Prodrug Strategy
    OPEN Palladium-Mediated Dealkylation of SUBJECT AREAS: N-Propargyl-Floxuridine as a CHEMOTHERAPY CHEMICAL TOOLS Bioorthogonal Oxygen-Independent DRUG DISCOVERY AND DEVELOPMENT Prodrug Strategy Jason T. Weiss, Neil O. Carragher & Asier Unciti-Broceta Received 2 December 2014 Edinburgh Cancer Research UK Centre, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road Accepted South, Edinburgh EH4 2XR, UK. 26 February 2015 Published 19 March 2015 Herein we report the development and biological screening of a bioorthogonal palladium-labile prodrug of the nucleoside analogue floxuridine, a potent antineoplastic drug used in the clinic to treat advanced cancers. N-propargylation of the N3 position of its uracil ring resulted in a vast reduction of its biological activity (,6,250-fold). Cytotoxic properties were bioorthogonally rescued in cancer cell culture by Correspondence and heterogeneous palladium chemistry both in normoxia and hypoxia. Within the same environment, the requests for materials reported chemo-reversible prodrug exhibited up to 1,450-fold difference of cytotoxicity whether it was in the absence or presence of the extracellular palladium source, underlining the precise modulation of bioactivity should be addressed to enabled by this bioorthogonally-activated prodrug strategy. A.U.-B. (Asier.Unciti- [email protected]. uk) ioorthogonally-activated prodrug therapies are a heterogeneous group of experimentally and clinically- used therapeutic strategies that are founded on a common principle: the site-specific activation of phar- B maceutical substances by the mediation of non-biological, non-perturbing physical or chemical stimuli. While the nature and properties of the triggering stimulus can be manifestly diverse and seemingly unrelated (e.g.
    [Show full text]
  • Imuran Data Sheet
    NEW ZEALAND DATA SHEET 1. IMURAN 25mg, 50mg Imuran tablets (azathioprine 25mg, 50mg) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 25mg, 50 mg azathioprine BP. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM 25mg: Orange tablet, film coated, round, biconvex, unscored, branded IM2. 50mg: Yellow tablet, film coated, round biconvex, scored, branded IM5. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications IMURAN is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and procedures which influence the immune response. Therapeutic effect may be evident only after weeks or months and can include a steroid- sparing effect, thereby reducing the toxicity associated with high dosage and prolonged usage of corticosteroids. IMURAN, in combination with corticosteroids and/or other immunosuppressive agents and procedures, is indicated to enhance the survival of organ transplants, such as renal transplants, cardiac transplants, and hepatic transplants; and to reduce the corticosteroid requirements of renal transplant recipients. IMURAN is indicated for the treatment of moderate to severe Crohn’s disease in patients in whom corticosteroid therapy is required, in patients who cannot tolerate corticosteroid therapy, or in patients whose disease is refractory to other standard first line therapy. IMURAN, either alone or more usually in combination with corticosteroids and/or other medicines and procedures, has been used with clinical benefit (which may include reduction of dosage or discontinuation of corticosteroids) in a proportion of patients suffering from the following: • severe rheumatoid arthritis; • systemic lupus erythematosus; • dermatomyositis and polymyositis; • auto-immune chronic active hepatitis; • pemphigus vulgaris; • polyarteritis nodosa; • auto-immune haemolytic anaemia; • chronic refractory idiopathic thrombocytopenic purpura; • ulcerative colitis.
    [Show full text]
  • The Universe of Normal and Cancer Cell Line Responses to Anticancer Treatment: Lessons for Cancer Therapy
    The universe of normal and cancer cell line responses to anticancer treatment: Lessons for cancer therapy Alexei Vazquez Department of Radiation Oncology, The Cancer Institute of New Jersey and UMDNJ-Robert Wood Johnson Medical School. 120 Albany Street, New Brunswick, NJ 08901, USA Abstract According to the Surveillance Epidemiology and End Results report, 1,479,350 men and women will be diagnosed with and 562,340 will die of cancer of all sites in 2009, indicating that about 40% of the cancer patients do not respond well to current anticancer therapies. Using tumor and normal tissue cell lines as a model, we show this high mortality rate is rooted in inherent features of anticancer treatments. We obtain that, while in average anticancer treatments exhibit a two fold higher efficacy when applied to cancer cells, the response distribution of cancer and normal cells significantly overlap. Focusing on specific treatments, we provide evidence indicating that the therapeutic index is proportional to the fraction of cancer cell lines manifesting significantly good responses, and propose the latter as a quantity to identify compounds with best potential for anticancer therapy. We conclude that there is no single treatment targeting all cancer cell lines at a non-toxic dose. However, there are effective treatments for specific cancer cell lines, which, when used in a personalized manner or applied in combination, can target all cancer cell lines. Background a collaboration between The Cancer Genome Project at the Wellcome Trust Sanger Institute Cell culture studies are the starting point of most (UK) and the Center for Molecular Therapeutics screens for anticancer treatments [1, 2].
    [Show full text]
  • Azathioprine As a Steroid Sparing Agent in Leprosy Type 2 Reactions: Report of Nine Cases
    Lepr Rev (2011) 82, 304–309 CASE REPORT Azathioprine as a steroid sparing agent in leprosy Type 2 reactions: Report of nine cases SANDRA MARIA BARBOSA DURA˜ ES*, SIMONE DE ABREU NEVES SALLES**, VERONICA RODRIGUES BOGADO LEITE*** & MORGANA OHIRA GAZZETA**** *Adjunct Professor of Dermatology at Universidade Federal Fluminense, Rio de Janeiro, Brazil **Assistant Professor of Dermatology at Universidade Federal Fluminense, Rio de Janeiro, Brazil ***Graduate Student in Dermatology, Universidade Federal Fluminense, Rio de Janeiro, Brazil ****Medical student at Universidade Federal Fluminense, Rio de Janeiro, Brazil Accepted for publication 06 April 2011 Introduction Glucocorticosteroids (GCS) are the main therapeutic agent used to treat leprosy reactions. Some patients have prolonged reactions and require prolonged therapy with GCS.1,2 Corticosteroid-sparing agents have been used especially in patients with rheumatological diseases to reduce the GCS doses required to control the disease, or as an alternative to GCS, and to reduce side effects. The literature contains few experiences in the use of such GCS sparing agents in leprosy reactions. After methotrexate (whose use is widespread in psoriasis), azathioprine is the immunosuppressant most widely used by dermatologists because of its immunosuppressive effect, which is superior to methotrexate, has less serious side effects than cyclosporine, and a lower cost than that of mycophenolate, tracolimus and sirolimus. These factors guided our predilection for the use of azathioprine over other immunosuppressants since we started using it in 1996, yet there was no publication about its use in leprosy reactions. From 2003 onwards articles began to emerge on the use of azathioprine in leprosy reactions. In the treatment of Type 1 reactions, when followed by prednisolone, it has been found to provide results comparable to those with prednisolone alone,3 thus possibly Correspondence to: Sandra Maria Barbosa Dura˜es, Hospital Universita´rio Antonio Pedro–Universidade Federal Fluminense, Av.
    [Show full text]